Silvio Traversa
Hoofd Techniek/Wetenschap/O&O bij SIENNA BIOPHARMACEUTICALS, INC.
Actieve functies van Silvio Traversa
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-12-2016 | - |
Loopbaan van Silvio Traversa
Eerdere bekende functies van Silvio Traversa
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Creabilis Therapeutics Srl
 Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Hoofd Techniek/Wetenschap/O&O | 01-10-2007 | 01-12-2016 |
| Corporate Officer/Principal | 01-02-2005 | 01-10-2007 | |
| Industria Farmaceutica Serono SpA | Corporate Officer/Principal | - | - |
Opleiding van Silvio Traversa
| University of Turin | Doctorate Degree |
| Harvard Business School | Graduate Degree |
Statistieken
Internationaal
| Italië | 4 |
| Verenigde Staten | 3 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectoraal
| Consumer Services | 3 |
| Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| Industria Farmaceutica Serono SpA | |
Creabilis Therapeutics Srl
Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Health Technology |
- Beurs
- Insiders
- Silvio Traversa
- Ervaring
